Nicola A Illingworth

发表

Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.

A. Brancale, C. Simons, J. Armstrong, 2012, Bioorganic & medicinal chemistry.

Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.

M. Ingelman-Sundberg, P. Loadman, S. Mkrtchian, 2013, Journal of medicinal chemistry.

Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma

A. Boddy, M. Cole, G. Veal, 2012, Clinical Cancer Research.

Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.

A. Brancale, C. Simons, J. Armstrong, 2012, Bioorganic & medicinal chemistry.

The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide.

D. Jamieson, A. Neilson, Shaun Martin, 2011, Oncology reports.

Role of UDP-Glucuronosyltransferase Isoforms in 13-cis Retinoic Acid Metabolism in Humans

A. Boddy, G. Veal, A. Daly, 2010, Drug Metabolism and Disposition.

Chemical Therapeutics Discovery & Preclinical Development Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P 450 1 A 1 in Human Transitional Cell Carcinoma of the Bladder

P. Cooper, P. Loadman, L. Patterson, 2013 .

Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder

P. Cooper, P. Loadman, L. Patterson, 2012, Molecular Cancer Therapeutics.

Novel micelles based on amphiphilic branched PEG as carriers for fenretinide.

M. Falconi, I. Orienti, G. Teti, 2012, Nanomedicine : nanotechnology, biology, and medicine.